Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Spyre Therapeutics Inc. (SYRE)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/27/2025: SYRE (1-star) is a SELL. SELL since 3 days. Profits (-4.84%). Updated daily EoD!
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
11 Analysts rated it
These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.
Year Target Price $54.44
Year Target Price $54.44
| 10 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Under performing |
| 0 | Sell |
Analysis of Past Performance
Type Stock | Historic Profit -44.3% | Avg. Invested days 23 | Today’s Advisory SELL |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 918.58M USD | Price to earnings Ratio - | 1Y Target Price 53.9 |
Price to earnings Ratio - | 1Y Target Price 53.9 | ||
Volume (30-day avg) - | Beta 2.73 | 52 Weeks Range 10.91 - 40.26 | Updated Date 06/29/2025 |
52 Weeks Range 10.91 - 40.26 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.06 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -25.34% | Return on Equity (TTM) -65.82% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 764231198 | Price to Sales(TTM) 650.22 |
Enterprise Value 764231198 | Price to Sales(TTM) 650.22 | ||
Enterprise Value to Revenue 1964.91 | Enterprise Value to EBITDA -7.96 | Shares Outstanding 60353600 | Shares Floating 46623126 |
Shares Outstanding 60353600 | Shares Floating 46623126 | ||
Percent Insiders 8.71 | Percent Institutions 106.07 |
Analyst Ratings
Rating 4.82 | Target Price 54.44 | Buy - | Strong Buy 10 |
Buy - | Strong Buy 10 | ||
Hold 1 | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Spyre Therapeutics Inc.
Company Overview
History and Background
Spyre Therapeutics, Inc. is a clinical-stage biotechnology company founded in 2022. It focuses on developing antibody therapies to treat inflammatory bowel disease (IBD). The company's strategy involves acquiring and advancing promising clinical-stage assets.
Core Business Areas
- Antibody Therapeutics Development: Spyre focuses on the development of antibody therapeutics targeting key inflammatory pathways in IBD.
- Clinical Trials: The company conducts clinical trials to evaluate the safety and efficacy of its therapeutic candidates.
- Drug Discovery and Acquisition: Spyre actively seeks to acquire and develop novel therapies for IBD.
Leadership and Structure
Spyre Therapeutics is led by a management team with experience in drug development and biotechnology. The organizational structure includes teams focused on research, clinical development, and business operations.
Top Products and Market Share
Key Offerings
- SPY001 (Satralizumab Biosimilar): SPY001 is a biosimilar candidate to Roche's Satralizumab, designed for subcutaneous administration. It aims to target the IL-6 pathway. There is currently no market share data since it is in development. Competitors include Roche (Satralizumab) and other companies developing IL-6 inhibitors.
- SPY002 (TL1A antibody): SPY002 is a monoclonal antibody targeting TL1A. There is currently no market share data since it is in development. Competitors include Roivant Sciences (RVT) and other companies developing TL1A inhibitors.
Market Dynamics
Industry Overview
The IBD therapeutics market is characterized by significant unmet needs and ongoing innovation, with a mix of established therapies and emerging biological treatments. The market is driven by the increasing prevalence of IBD and the demand for more effective and targeted therapies.
Positioning
Spyre Therapeutics aims to establish a leading position in the IBD therapeutics market by developing innovative antibody therapies that address key unmet needs. Their strategy involves acquiring and advancing clinical-stage assets to accelerate development timelines.
Total Addressable Market (TAM)
The global IBD market is expected to reach approximately $25 billion by 2030. Spyre is positioned to capture a portion of this market by focusing on novel therapeutic targets and differentiated antibody therapies.
Upturn SWOT Analysis
Strengths
- Experienced Management Team
- Focus on a high unmet need market (IBD)
- Promising clinical-stage pipeline
Weaknesses
- Early stage company with limited financial resources
- High dependence on clinical trial outcomes
- Reliance on acquisitions for pipeline growth
Opportunities
- Acquisition of additional assets
- Positive clinical trial results leading to regulatory approval
- Partnerships with larger pharmaceutical companies
Threats
- Clinical trial failures
- Competition from established pharmaceutical companies
- Regulatory hurdles
- Patent disputes
Competitors and Market Share
Key Competitors
- JNJ
- PFE
- BMY
- RVT
Competitive Landscape
Spyre faces competition from established pharmaceutical companies with approved IBD therapies, as well as other biotech companies developing novel treatments. Spyre's advantage lies in its focus on differentiated antibody therapies and its acquisition strategy.
Major Acquisitions
Ad u09aau09cbu09b0u09cdu099f Sciences, Inc
- Year: 2023
- Acquisition Price (USD millions): 22.5
- Strategic Rationale: The acquisition of Ad u09aau09cbu09b0u09cdu099f Sciences strengthened their IP portfolio and lead to SPY002.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is defined by preclinical and clinical trial milestones, as well as acquisitions of pipeline assets.
Future Projections: Future growth depends on successful clinical trial outcomes, regulatory approvals, and commercialization of therapeutic candidates. Analyst estimates would focus on projected peak sales for key products.
Recent Initiatives: Recent initiatives include advancing the clinical development of SPY001 and SPY002, and evaluating potential acquisitions of additional assets.
Summary
Spyre Therapeutics is an early-stage biotech company with a focus on IBD therapies, showing promise through its pipeline of antibody therapeutics. Its success hinges on positive clinical trial results and effective pipeline expansion through strategic acquisitions. Key watch-outs include clinical trial risks, competition from established players, and managing financial resources. However the company may not be able to compete with the much larger pharmaceutical companies and may become an acquisition target in the future.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Spyre Therapeutics Inc. website
- SEC filings
- Analyst reports
- Industry publications
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Investment decisions should be based on individual research and consultation with a qualified financial advisor. Market share data is estimated.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Spyre Therapeutics Inc.
Exchange NASDAQ | Headquaters Waltham, MA, United States | ||
IPO Launch date 2016-04-07 | CEO & Director Dr. Cameron Turtle DPHIL, Ph.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 73 | Website https://www.spyre.com |
Full time employees 73 | Website https://www.spyre.com | ||
Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. The company was incorporated in 2013 and is based in Waltham, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.